Argenica Therapeutics (ASX:AGN) received a full clinical hold letter from the US Food and Drug Administration (FDA) on the reasons for the imposed clinical hold and the information required to lift the hold regarding its investigational new drug application, enable clinical trials of the ARG-007 drug candidate in acute ischaemic stroke in the US, according to a Thursday Australian bourse filing.
The regulator requested additional information to ensure that the proposed trial dosing for a US trial can be achieved safely in humans, and the firm plans to use its phase two acute ischaemic stroke trial safety data, which will be available in September, as part of its response.
The FDA also requested Argenica to conduct three additional in vitro cell culture studies with clinical research organizations to address identified gaps in data. It also asked the firm to include more detail on the phase one data in the investigational brochure.
The firm's shares fell 1% in recent trading on Thursday.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。